Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months

Podobne knjige/članki

• A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children
  od: Bélard, Sabine, et al.
  Izdano: (2011)
• Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon
  od: Mordmüller, Benjamin, et al.
  Izdano: (2010)
• Malariometric indices from Iganga, Uganda: baseline characterization in preparation of GMZ2 vaccine trial
  od: Kaddumukasa, Mark, et al.
  Izdano: (2014)
• Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults
  od: Nouatin, Odilon, et al.
  Izdano: (2020)
• Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
  od: Sirima, Sodiomon B., et al.
  Izdano: (2009)